Between cash on hand and a recent arrangement for an equity line of credit for up to $8M, management believes that through its measures, it has extended its cash to maintain activities into late 2025. This is expected to enable Quoin to continue moving QRX003 ahead through NS clinical trials and recent FDA clearance to recruit subjects 14 and older also allows Quoin to broaden the pool of people eligible to participate in the studies and thereby facilitate recruitment efforts. Expanding the number of participants to an aggregate of 50 NS subjects also is expected to contribute to a more robust database to present for potential regulatory approval.